Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease.

Nakamura A, Kodera R, Sakamoto N, Ujike H, Wada J, Shikata K, Makino H.

Diabetol Int. 2018 Jan 18;9(3):179-188. doi: 10.1007/s13340-018-0342-6. eCollection 2018 Jul.

2.

The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study.

Umebayashi R, Uchida HA, Okuyama Y, Kakio Y, Hanayama Y, Shikata K, Wada J.

Biomarkers. 2019 May;24(3):255-261. doi: 10.1080/1354750X.2018.1548033. Epub 2018 Nov 29.

PMID:
30444137
3.

Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease.

Ohmichi T, Kasai T, Kosaka T, Shikata K, Tatebe H, Ishii R, Shinomoto M, Mizuno T, Tokuda T.

PLoS One. 2018 Jul 25;13(7):e0201260. doi: 10.1371/journal.pone.0201260. eCollection 2018.

4.

Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy.

Tanaka K, Sugiyama H, Yamanari T, Mise K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Tanabe K, Eguchi J, Ohmoto Y, Shikata K, Wada J.

Nephrology (Carlton). 2018 Sep;23(9):855-862. doi: 10.1111/nep.13444. Epub 2018 Jul 26.

5.

Identification of Novel Urinary Biomarkers for Predicting Renal Prognosis in Patients With Type 2 Diabetes by Glycan Profiling in a Multicenter Prospective Cohort Study: U-CARE Study 1.

Mise K, Imamura M, Yamaguchi S, Teshigawara S, Tone A, Uchida HA, Eguchi J, Nakatsuka A, Ogawa D, Yoshida M, Yamada M, Shikata K, Wada J.

Diabetes Care. 2018 Aug;41(8):1765-1775. doi: 10.2337/dc18-0030. Epub 2018 Jun 21.

PMID:
29930140
6.

Urine Trefoil Factors as Prognostic Biomarkers in Chronic Kidney Disease.

Yamanari T, Sugiyama H, Tanaka K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Kano Y, Mise K, Ohmoto Y, Shikata K, Wada J.

Biomed Res Int. 2018 Apr 3;2018:3024698. doi: 10.1155/2018/3024698. eCollection 2018.

7.

Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.

Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Kawano R, Tabuchi Y, Yoshioka T, Ihara N, Hosokawa T, Takayama K, Shikata K, Taguchi T.

Med Oncol. 2018 Mar 16;35(4):55. doi: 10.1007/s12032-018-1116-5.

PMID:
29549536
8.

A Comparative Chromosome Mapping Study in Japanese Podismini Grasshoppers (Orthoptera: Acrididae: Melanoplinae).

Grzywacz B, Tatsuta H, Shikata KI, Warchałowska-Śliwa E.

Cytogenet Genome Res. 2018;154(1):37-44. doi: 10.1159/000487063. Epub 2018 Mar 7.

PMID:
29510395
9.

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.

Kodera R, Shikata K, Nakamura A, Okazaki S, Nagase R, Nakatou T, Haisa S, Hida K, Miyashita K, Makino H.

Intern Med. 2017;56(6):605-613. doi: 10.2169/internalmedicine.56.7428. Epub 2017 Mar 17.

10.

Genetic analysis of revertants isolated from the rod-fragile fliF mutant of Salmonella.

Komatsu H, Hayashi F, Sasa M, Shikata K, Yamaguchi S, Namba K, Oosawa K.

Biophys Physicobiol. 2016 Jan 28;13:13-25. eCollection 2016.

11.

Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.

Taguchi R, Shikata K, Furuya Y, Hirakawa T, Ino M, Shin K, Shibata H.

Psychoneuroendocrinology. 2017 Jan;75:110-115. doi: 10.1016/j.psyneuen.2016.10.025. Epub 2016 Oct 29.

PMID:
27810704
12.

Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.

Taguchi R, Shikata K, Furuya Y, Ino M, Shin K, Shibata H.

Behav Brain Res. 2016 Oct 1;312:138-47. doi: 10.1016/j.bbr.2016.06.017. Epub 2016 Jun 11.

PMID:
27297028
13.

[The management of diabetic patients on hemodialysis or peritoneal dialysis].

Kinomura M, Sugiyama H, Shikata K.

Nihon Rinsho. 2016 Apr;74 Suppl 2:212-6. Japanese. No abstract available.

PMID:
27266090
14.

Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study.

Ikeda F, Shikata K, Hata J, Fukuhara M, Hirakawa Y, Ohara T, Mukai N, Nagata M, Yoshida D, Yonemoto K, Esaki M, Kitazono T, Kiyohara Y, Ninomiya T.

J Epidemiol. 2016 Dec 5;26(12):629-636. Epub 2016 Jun 4.

15.

Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.

Kodera R, Shikata K.

J Diabetes Investig. 2016 Jan;7(1):29-31. doi: 10.1111/jdi.12380. Epub 2015 Jun 30. Review. No abstract available.

16.

Cognitive and affective functions in diabetic patients associated with diabetes-related factors, white matter abnormality and aging.

Hishikawa N, Yamashita T, Deguchi K, Wada J, Shikata K, Makino H, Abe K.

Eur J Neurol. 2015 Feb;22(2):313-21. doi: 10.1111/ene.12568. Epub 2014 Sep 15.

PMID:
25220803
17.

Factors associated with remission and/or regression of microalbuminuria in type 2 diabetes mellitus.

Ono T, Shikata K, Obika M, Miyatake N, Kodera R, Hirota D, Wada J, Kataoka H, Ogawa D, Makino H.

Acta Med Okayama. 2014;68(4):235-41.

18.
19.

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):828-33. doi: 10.1016/j.bbrc.2013.12.049. Epub 2013 Dec 14.

PMID:
24342619
20.

Trends in the incidence and survival of intracerebral hemorrhage by its location in a Japanese community.

Gotoh S, Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Fukuhara M, Ikeda F, Shikata K, Kamouchi M, Kitazono T, Kiyohara Y.

Circ J. 2014;78(2):403-9. Epub 2013 Nov 23.

21.

Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study.

Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, Shikata K, Yoshida D, Matsumoto T, Kitazono T, Kiyohara Y.

Cardiovasc Diabetol. 2013 Nov 7;12:164. doi: 10.1186/1475-2840-12-164.

22.

Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009).

Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M, Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T, Kiyohara Y.

Circulation. 2013 Sep 10;128(11):1198-205. doi: 10.1161/CIRCULATIONAHA.113.002424. Epub 2013 Jul 31.

PMID:
23902756
23.

Prediction of relaxin-3-induced downstream pathway resulting in anxiolytic-like behaviors in rats based on a microarray and peptidome analysis.

Nakazawa CM, Shikata K, Uesugi M, Katayama H, Aoshima K, Tahara K, Takahashi E, Hida T, Shibata H, Ogura H, Seiki T, Oda Y, Kuromitsu J, Miyamoto N.

J Recept Signal Transduct Res. 2013 Aug;33(4):224-33. doi: 10.3109/10799893.2012.756895. Epub 2013 May 22.

PMID:
23697547
24.

Genomic and chromosomal distribution patterns of various repeated DNA sequences in wheat revealed by a fluorescence in situ hybridization procedure.

Komuro S, Endo R, Shikata K, Kato A.

Genome. 2013 Mar;56(3):131-7. doi: 10.1139/gen-2013-0003. Epub 2013 Feb 21.

PMID:
23659696
25.

Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy.

Nakamura A, Shikata K, Nakatou T, Kitamura T, Kajitani N, Ogawa D, Makino H.

J Diabetes Investig. 2013 Mar 18;4(2):195-201. doi: 10.1111/jdi.12004. Epub 2012 Nov 20.

26.

Microinflammation in the pathogenesis of diabetic nephropathy.

Shikata K, Makino H.

J Diabetes Investig. 2013 Mar 18;4(2):142-9. doi: 10.1111/jdi.12050. Review.

27.

Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice.

Sato-Horiguchi C, Ogawa D, Wada J, Tachibana H, Kodera R, Eguchi J, Nakatsuka A, Terami N, Shikata K, Makino H.

Nephron Exp Nephrol. 2012;121(3-4):e97-e108. doi: 10.1159/000343102. Epub 2013 Jan 10. Erratum in: Nephron Exp Nephrol. 2013;123(3-4):46.

PMID:
23307263
28.

Case of emphysematous cholecystitis in a patient with type 2 diabetes mellitus associated with schizophrenia.

Ogawa A, Shikata K, Uchida HA, Shinoura S, Yokomichi N, Ogawa D, Sato-Horiguchi C, Yagi T, Wada J, Makino H.

J Diabetes Investig. 2012 Dec 20;3(6):534-5. doi: 10.1111/j.2040-1124.2012.00232.x. Epub 2012 Aug 21.

29.

Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy.

Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, Eguchi J, Sato-Horiguchi C, Uchida HA, Shikata K, Makino H.

J Am Soc Nephrol. 2012 Nov;23(11):1835-46. doi: 10.1681/ASN.2012010022. Epub 2012 Oct 18.

30.

Diabetes mellitus and cancer risk: review of the epidemiological evidence.

Shikata K, Ninomiya T, Kiyohara Y.

Cancer Sci. 2013 Jan;104(1):9-14. doi: 10.1111/cas.12043. Epub 2012 Dec 6. Review.

31.

Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.

Takeda K, Terauchi T, Hashizume M, Shikata K, Taguchi R, Murata-Tai K, Fujisawa M, Takahashi Y, Shin K, Ino M, Shibata H, Yonaga M.

Bioorg Med Chem. 2012 Nov 15;20(22):6559-78. doi: 10.1016/j.bmc.2012.09.028. Epub 2012 Sep 23.

PMID:
23062820
32.

Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.

Takahashi Y, Hashizume M, Shin K, Terauchi T, Takeda K, Hibi S, Murata-Tai K, Fujisawa M, Shikata K, Taguchi R, Ino M, Shibata H, Yonaga M.

J Med Chem. 2012 Oct 11;55(19):8450-63. doi: 10.1021/jm300864p. Epub 2012 Oct 1.

PMID:
22971011
33.

Phenotypic change of macrophages in the progression of diabetic nephropathy; sialoadhesin-positive activated macrophages are increased in diabetic kidney.

Nagase R, Kajitani N, Shikata K, Ogawa D, Kodera R, Okada S, Kido Y, Makino H.

Clin Exp Nephrol. 2012 Oct;16(5):739-48. doi: 10.1007/s10157-012-0625-3. Epub 2012 Apr 14.

34.

Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.

Shikata K, Ninomiya T, Yonemoto K, Ikeda F, Hata J, Doi Y, Fukuhara M, Matsumoto T, Iida M, Kitazono T, Kiyohara Y.

Scand J Gastroenterol. 2012 Jun;47(6):669-75. doi: 10.3109/00365521.2012.658855. Epub 2012 Mar 20.

PMID:
22428879
35.

Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin.

Miyamoto S, Shikata K, Miyasaka K, Okada S, Sasaki M, Kodera R, Hirota D, Kajitani N, Takatsuka T, Kataoka HU, Nishishita S, Sato C, Funakoshi A, Nishimori H, Uchida HA, Ogawa D, Makino H.

Diabetes. 2012 Apr;61(4):897-907. doi: 10.2337/db11-0402. Epub 2012 Feb 22.

36.

A commentary on the VITAL study: Does vitamin D (receptor activation) protect against nephropathy in type 2 diabetes?

Okada S, Shikata K.

J Diabetes Investig. 2012 Feb 20;3(1):36-8. doi: 10.1111/j.2040-1124.2011.00161.x. No abstract available.

38.

Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam.

Maehata Y, Esaki M, Morishita T, Kochi S, Endo S, Shikata K, Kobayashi H, Matsumoto T.

J Gastroenterol. 2012 Apr;47(4):387-93. doi: 10.1007/s00535-011-0501-z. Epub 2011 Dec 15.

PMID:
22170412
39.

[Microinflammation in diabetic nephropathy].

Ogawa D, Shikata K.

Nihon Jinzo Gakkai Shi. 2011;53(7):1021-6. Review. Japanese. No abstract available.

PMID:
22073867
40.

High glucose increases metallothionein expression in renal proximal tubular epithelial cells.

Ogawa D, Asanuma M, Miyazaki I, Tachibana H, Wada J, Sogawa N, Sugaya T, Kitamura S, Maeshima Y, Shikata K, Makino H.

Exp Diabetes Res. 2011;2011:534872. doi: 10.1155/2011/534872. Epub 2011 Sep 22.

41.

Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy.

Watanabe N, Shikata K, Shikata Y, Sarai K, Omori K, Kodera R, Sato C, Wada J, Makino H.

Acta Med Okayama. 2011 Aug;65(4):247-57.

42.

[Pathology of diabetic nephropathy].

Kodera R, Shikata K.

Nihon Rinsho. 2010 Nov;68 Suppl 9:370-4. Japanese. No abstract available.

PMID:
21667490
43.

[Microinflammation in diabetic microvascular complications].

Kajitani N, Shikata K.

Nihon Rinsho. 2010 Nov;68 Suppl 9:61-4. Japanese. No abstract available.

PMID:
21661144
44.

Emphysematous cystitis in a patient with type 2 diabetes mellitus.

Toyota N, Ogawa D, Ishii K, Hirata K, Wada J, Shikata K, Makino H.

Acta Med Okayama. 2011 Apr;65(2):129-33.

45.

The macrophage is a key factor in renal injuries caused by glomerular hyperfiltration.

Sasaki M, Shikata K, Okada S, Miyamoto S, Nishishita S, Kataoka HU, Sato C, Wada J, Ogawa D, Makino H.

Acta Med Okayama. 2011 Apr;65(2):81-9.

46.

The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan.

Miyatake N, Shikata K, Makino H, Numata T.

Environ Health Prev Med. 2011 May;16(3):191-5. doi: 10.1007/s12199-010-0183-9. Epub 2010 Oct 15.

47.

Colorectal cancer screening with odour material by canine scent detection.

Sonoda H, Kohnoe S, Yamazato T, Satoh Y, Morizono G, Shikata K, Morita M, Watanabe A, Morita M, Kakeji Y, Inoue F, Maehara Y.

Gut. 2011 Jun;60(6):814-9. doi: 10.1136/gut.2010.218305. Epub 2011 Jan 31.

48.

Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice.

Matsushita Y, Ogawa D, Wada J, Yamamoto N, Shikata K, Sato C, Tachibana H, Toyota N, Makino H.

Diabetes. 2011 Mar;60(3):960-8. doi: 10.2337/db10-1361. Epub 2011 Jan 26.

49.

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H.

Diabetologia. 2011 Apr;54(4):965-78. doi: 10.1007/s00125-010-2028-x. Epub 2011 Jan 21.

PMID:
21253697
50.

Intercellular adhesion molecule-1 plays a critical role in glomerulosclerosis after subtotal nephrectomy.

Kido Y, Ogawa D, Shikata K, Sasaki M, Nagase R, Okada S, Usui Kataoka H, Wada J, Makino H.

Clin Exp Nephrol. 2011 Apr;15(2):212-9. doi: 10.1007/s10157-010-0388-7. Epub 2010 Dec 23.

PMID:
21181224

Supplemental Content

Loading ...
Support Center